<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723915</url>
  </required_header>
  <id_info>
    <org_study_id>NU 18I01</org_study_id>
    <secondary_id>NCI-2018-02319</secondary_id>
    <secondary_id>STU00207577</secondary_id>
    <secondary_id>NU 18I01</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <nct_id>NCT03723915</nct_id>
  </id_info>
  <brief_title>Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer</brief_title>
  <official_title>A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well pembrolizumab in combination with&#xD;
      pelareorep work in treating patients with pancreatic cancer that has spread to other parts of&#xD;
      the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes&#xD;
      in the body's immune system and may interfere with the ability of tumor cells to grow and&#xD;
      spread. A virus, called reovirus (pelareorep), which has been changed in a certain way, may&#xD;
      be able to kill tumor cells without damaging normal cells. Giving pembrolizumab in&#xD;
      combination with pelareorep may work better in treating patients with advanced pancreatic&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall response rate (ORR) by Response Evaluation Criteria in Solid&#xD;
      Tumors (RECIST) version (v) 1.1 criteria of pembrolizumab in combination with Reovirus&#xD;
      Serotype 3 ? Dearing Strain (pelareorep).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine progression free survival by RECIST v 1.1 criteria, as well as 1- year,&#xD;
      2-year and median overall survival with pembrolizumab in combination with pelareorep.&#xD;
&#xD;
      II. To determine safety and tolerability of pembrolizumab and pelareorep when administered in&#xD;
      combination as determined by National Cancer Institute (NCI) Common Terminology Criteria for&#xD;
      Adverse Events (CTCAE) v 4.03.&#xD;
&#xD;
      III. To determine the effects (immune response) of pembrolizumab and pelareorep when&#xD;
      administered in combination as determined by analysis of pre-and post-treatment biopsies and&#xD;
      blood-based immune markers.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To measure the overall response rate (ORR) by using Immune-Modified Response Evaluation&#xD;
      Criteria in Solid Tumors (iRECIST) criteria, for the combination of pembrolizumab and&#xD;
      pelareorep.&#xD;
&#xD;
      II. To determine progression free survival by iRECIST criteria as well as 1-year, 2-year and&#xD;
      median overall survival with pembrolizumab in combination with pelareorep.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats&#xD;
      every 21 days for up to 32 courses in the absence of disease progression, unacceptable&#xD;
      toxicity, development of an inter-current illness that prevents further administration of&#xD;
      treatment, patient decides to withdraw, patients not experiencing clinical benefit in the&#xD;
      judgment of the Investigator, or the treating investigator determines that the patient should&#xD;
      be taken off treatment for any reason. Patients also receive Pelareorep IV over 60 minutes on&#xD;
      days 1, 2, 3, and 8 in course 1 and on days 1 and 8 of subsequent courses. Courses repeat&#xD;
      every 21 days for up to 24 months in the absence of disease progression, unacceptable&#xD;
      toxicity, development of an inter-current illness that prevents further administration of&#xD;
      treatment, patient decides to withdraw, patients not experiencing clinical benefit in the&#xD;
      judgment of the Investigator, or the treating investigator determines that the patient should&#xD;
      be taken off treatment for any reason. Patients who stop study therapy with stable disease&#xD;
      (SD) or better may be eligible for up to 1 year of additional Pelareorep and pembrolizumab&#xD;
      therapy if they progress after stopping study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the&#xD;
    interim analysis criteria to move onto Stage 2 of the Simon 2 stage design.&#xD;
  </why_stopped>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Actual">April 24, 2021</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1</measure>
    <time_frame>Last week of Cycle 3 (1 Cycle = 21 days)</time_frame>
    <description>To determine the overall response rate (ORR) by RECIST v 1.1 criteria for the combination of pembrolizumab with pelareorep. ORR is defined as the number of patients who have a complete or partial response to therapy (CR or PR). The Simon 2 stage design for this study requires 2 or more PR or CR in Stage 1 to continue accrual for Stage 2. Per RECIST v. 1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.&#xD;
Patients who have taken one dose of either study drug, and completed the first on study scan (last week of Cycle 3) are evaluable. If a patient drops out of the study before the first scan, due to clinical progression, they are evaluable and will not be replaced.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) by RECIST v 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Kaplan-Meier curves will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Survival by RECIST v 1.1</measure>
    <time_frame>At 1 year</time_frame>
    <description>Kaplan-Meier curves will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year Survival by RECIST v 1.1</measure>
    <time_frame>At 2 years</time_frame>
    <description>Kaplan-Meier curves will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS) by RECIST v 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Kaplan-Meier curves will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response Determined by Analysis of pre-and Post- Treatment Biopsies and Blood-based Immune Markers</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed for change using paired statistical methods such as paired t-tests or signed rank tests.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Stage III Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IV Pancreatic Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (pembrolizumab, wild-type reovirus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab, wild-type reovirus)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Wild-type Reovirus</intervention_name>
    <description>Given pelareorep IV</description>
    <arm_group_label>Treatment (pembrolizumab, wild-type reovirus)</arm_group_label>
    <other_name>Reolysin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed advanced (unresectable or metastatic)&#xD;
             pancreatic adenocarcinoma, documented objective radiographic progression and have&#xD;
             failed or not tolerated first-line therapy.&#xD;
&#xD;
               -  Note: First-line therapy denotes systemic chemotherapy for advanced pancreatic&#xD;
                  adenocarcinoma. Only one line of therapy is permitted in this setting. Intolerant&#xD;
                  to first line therapy are patients that have developed &gt;= grade 3 adverse events&#xD;
                  related to first line therapy and treating physician deems continuing of systemic&#xD;
                  chemotherapy would be detrimental to patient.&#xD;
&#xD;
          -  Patients must have confirmation of an existing formalin-fixed paraffin-embedded (FPPE)&#xD;
             tumor sample from archival tissue or from a fresh biopsy of a primary or metastatic&#xD;
             lesion at baseline, either as a block or unstained slides for performance of&#xD;
             correlative studies.&#xD;
&#xD;
               -  Note: Patients must undergo a fresh biopsy if archival tissue is not available.&#xD;
&#xD;
          -  Patients must have measurable disease as defined by RECIST v 1.1.&#xD;
&#xD;
          -  Any major surgery (except biopsies) must have occurred at least 28 days prior to first&#xD;
             day of study treatment.&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance score =&lt;&#xD;
             1.&#xD;
&#xD;
          -  Patients must have a life expectancy of &gt;= 6 months.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500 /mcL (with or without growth factor use).&#xD;
&#xD;
          -  Platelets &gt;= 100,000 / mcL.&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL, OR &gt;= 5.6 mmol/L with (if clinically indicated)/without&#xD;
             transfusion or erythropoietin [EPO] dependency).&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x upper limit of normal (ULN), OR measured or calculated&#xD;
             creatinine clearance (glomerular filtration rate [GFR] can also be used in place of&#xD;
             creatinine or creatinine clearance [CrCl]) &gt;= 60 mL/min for subject with creatinine&#xD;
             levels &gt; 1.5 x institutional ULN.&#xD;
&#xD;
               -  (Note: creatinine clearance should be calculated per institutional standard.)&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 x ULN, OR direct bilirubin =&lt; ULN for subjects with total&#xD;
             bilirubin levels &gt; 1.5 x ULN.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 x&#xD;
             ULN, OR =&lt; 5 x ULN for subjects with liver metastases.&#xD;
&#xD;
          -  Albumin &gt;= 2.5 mg/dL.&#xD;
&#xD;
          -  International normalized ratio (INR) or prothrombin time (PT) =&lt; 1.5 x ULN unless&#xD;
             subject is receiving anticoagulant therapy. For patients on anticoagulant therapy,&#xD;
             PT/INR must be within therapeutic range.&#xD;
&#xD;
          -  Activated partial thromboplastin time (aPTT) =&lt; 1.5 x ULN unless subject is receiving&#xD;
             anticoagulant therapy. For patients on anticoagulant therapy, PT/INR must be within&#xD;
             therapeutic range&#xD;
&#xD;
          -  Thyroid-stimulating hormone (TSH), thyroxine (T4) and corticotropin (ACTH) within&#xD;
             normal range (prior to registration).&#xD;
&#xD;
          -  Proteinuria within institutional normal or =&lt; grade 1 OR urinary protein &lt; 1 g/24&#xD;
             hours (hr) (prior to registration).&#xD;
&#xD;
          -  Female subject of childbearing potential must have a negative urine or serum pregnancy&#xD;
             within 7 days of registration. It is to be repeated on day 1 of study treatment,&#xD;
             before infusion, if it is done greater than 3 days of day 1. If the urine test is&#xD;
             positive or cannot be confirmed as negative, a serum pregnancy test is required.&#xD;
             Female subjects of childbearing potential must be willing to use an adequate method of&#xD;
             contraception (willing to use 2 methods of birth control or be surgically sterile, or&#xD;
             abstain from heterosexual activity), for the course of the study through 120 days&#xD;
             after the last dose of study medication. Should a female patient become pregnant or&#xD;
             suspect she is pregnant while participating in this study, she should inform her&#xD;
             treating physician immediately.&#xD;
&#xD;
               -  Note: A female of childbearing potential (FOCBP) is any woman (regardless of&#xD;
                  sexual orientation, having undergone a tubal ligation, or remaining celibate by&#xD;
                  choice) who meets the following criteria:&#xD;
&#xD;
                    -  Has not undergone a hysterectomy or bilateral oophorectomy&#xD;
&#xD;
                    -  Has had menses at any time in the preceding 12 consecutive months (and&#xD;
                       therefore has not been naturally postmenopausal for &gt; 12 months).&#xD;
&#xD;
          -  Male subjects of childbearing potential must agree to use an adequate method of&#xD;
             contraception or be surgically sterile or abstain from heterosexual activity, starting&#xD;
             with the first dose of study therapy through 120 days after the last dose of study&#xD;
             therapy.&#xD;
&#xD;
          -  Patients must have signed an informed consent indicating that the patient is aware of&#xD;
             the neoplastic nature of their disease and have been informed of the procedures of the&#xD;
             protocol, the experimental nature of the therapy, alternatives, potential benefits,&#xD;
             side effects, risks, and discomforts.&#xD;
&#xD;
          -  Patients must be willing and able to comply with scheduled visits, the treatment plan,&#xD;
             and laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior first day of&#xD;
             study drug or those who have not recovered from adverse events due to agents&#xD;
             administered more than 4 weeks from cycle 1 day 1 are not eligible.&#xD;
&#xD;
          -  Patients who have a diagnosis of immunodeficiency or is receiving systemic steroid&#xD;
             therapy or any other form of immunosuppressive therapy within 7 days prior to the&#xD;
             first dose of study treatment are excluded.&#xD;
&#xD;
               -  Note: If patient is on high dose of steroid therapy, it needs to be brought down&#xD;
                  to &lt; 10 mg prednisone or equivalent for at least 7 days prior to day 1 of study&#xD;
                  treatment.&#xD;
&#xD;
          -  Patients receiving any other investigational agents for at least 4 weeks before the&#xD;
             first dose of study treatment are not eligible.&#xD;
&#xD;
          -  Patients with a known history of active TB (Bacillus tuberculosis) are excluded.&#xD;
&#xD;
          -  Patients with a hypersensitivity to pembrolizumab or any of its excipients are&#xD;
             excluded.&#xD;
&#xD;
          -  Patients who have had a prior anti-cancer monoclonal antibody (mAb) within 28 days&#xD;
             prior to study day 1 or who has not recovered (i.e., =&lt; grade 1 or at baseline) from&#xD;
             adverse events due to agents administered more than 4 weeks earlier.&#xD;
&#xD;
          -  Patients who have had prior chemotherapy, targeted small molecule therapy, or&#xD;
             radiation therapy within 28 days prior to study day 1 or who has not recovered (i.e.,&#xD;
             NCI CTCAE version 4.03 grade =&lt; 1 or at baseline) from adverse events due to a&#xD;
             previously administered agent are not eligible.&#xD;
&#xD;
               -  Note: If subject received major surgery, they must have recovered adequately from&#xD;
                  the toxicity and/or complications from the intervention prior to starting&#xD;
                  therapy.&#xD;
&#xD;
               -  Exceptions to this criteria are:&#xD;
&#xD;
                    -  Subjects with =&lt; grade 2 neuropathy or alopecia are an exception to this&#xD;
                       criterion and may qualify for the study.&#xD;
&#xD;
          -  Patients receiving palliative radiation are eligible for this study. Palliative&#xD;
             radiation is allowed during treatment as well. Patients with a known additional&#xD;
             malignancy that is progressing or requires active treatment within the past 5 years&#xD;
             are excluded. Exceptions include basal cell carcinoma of the skin or squamous cell&#xD;
             carcinoma of the skin that has undergone potentially curative therapy or in situ&#xD;
             cervical cancer.&#xD;
&#xD;
          -  Patients with a known active central nervous system (CNS) metastases and/or&#xD;
             carcinomatous meningitis are excluded.&#xD;
&#xD;
               -  Note: Subjects with previously treated brain metastases may participate provided&#xD;
                  they are stable (without evidence of progression by imaging for at least four&#xD;
                  weeks prior to the first dose of trial treatment and any neurologic symptoms have&#xD;
                  returned to baseline), have no evidence of new or enlarging brain metastases, and&#xD;
                  are not using steroids for at least 7 days prior to trial treatment.&#xD;
&#xD;
               -  This exception does not include carcinomatous meningitis, which is excluded&#xD;
                  regardless of clinical stability.&#xD;
&#xD;
          -  Patients with an active autoimmune disease that has required systemic treatment in the&#xD;
             past 2 years (i.e. with use of disease modifying agents, corticosteroids or&#xD;
             immunosuppressive drugs) are excluded.&#xD;
&#xD;
               -  Note: Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid&#xD;
                  replacement therapy for adrenal or pituitary insufficiency, etc.) is not&#xD;
                  considered a form of systemic treatment.&#xD;
&#xD;
          -  Patients with a history of (non-infectious) pneumonitis that required steroids or&#xD;
             current pneumonitis are excluded.&#xD;
&#xD;
          -  Patients with an active infection requiring systemic therapy are excluded.&#xD;
&#xD;
          -  Patients with a history or current evidence of any condition, therapy, or laboratory&#xD;
             abnormality that might confound the results of the trial, interfere with the subject?s&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator are excluded.&#xD;
&#xD;
          -  Patients with a known psychiatric or substance abuse disorders that would interfere&#xD;
             with cooperation with the requirements of the trial are excluded.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding, or expecting to conceive or father&#xD;
             children within the projected duration of the trial, starting with the pre-screening&#xD;
             or screening visit through 120 days after the last dose of trial treatment are&#xD;
             excluded.&#xD;
&#xD;
          -  Patients who have received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL2&#xD;
             agent are excluded.&#xD;
&#xD;
          -  Patients with a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2&#xD;
             antibodies) are excluded.&#xD;
&#xD;
          -  Patients with a known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg]&#xD;
             reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA]&#xD;
             [qualitative] is detected) are excluded.&#xD;
&#xD;
          -  Patients who have received a live vaccine within 30 days of planned start of study&#xD;
             therapy are excluded.&#xD;
&#xD;
               -  Note: Seasonal influenza vaccines for injection are generally inactivated flu&#xD;
                  vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist)&#xD;
                  are live attenuated vaccines, and are not allowed.&#xD;
&#xD;
          -  Patients with clinically significant cardiac disease (New York Heart Association,&#xD;
             class III or IV including pre-existing arrhythmia, uncontrolled angina pectoris, and&#xD;
             myocardial infarction 1 year prior to registration, or grade 2 or higher compromised&#xD;
             left ventricular ejection fraction are excluded.&#xD;
&#xD;
          -  Patients who have dementia or altered mental status that would prohibit informed&#xD;
             consent are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devalingam Mahalingam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <results_first_submitted>November 24, 2020</results_first_submitted>
  <results_first_submitted_qc>December 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 20, 2021</results_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03723915/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened up to patient accrual on Nov. 2, 2018 with the first patient starting treatment Nov. 14, 2018 and an accrual goal of 34 patients. Stage 1 of the Simon 2 Stage design was completed on Jan 23, 2020, and the study was closed to accrual. The study did not meet the interim analysis criteria to continue to stage 2. Pharmacodynamic analysis is ongoing to identify biomarkers to predict response from therapy.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pembrolizumab 200 mg IV + Pelareorep 4.5x10^10 TCID_50</title>
          <description>Pembrolizumab will be administered on Day 1 of each cycle at 200 mg IV over 30 minutes.&#xD;
In Cycle 1, Pelareorep will be administered at a dose of 4.5x10 ^10 TCID_50 (Tissue Culture Infective Dose 50) over 60 minutes on Days 1, 2, 3 and 8. From Cycle 2 onwards, Pelareorep will be administered at a dose of 4.5x10^10 TCID_50 on Days 1 and 8.&#xD;
Pelareorep will be administered after completion of Pembrolizumab infusion on Day 1 of each cycle.&#xD;
Each cycle is 21 days (3 weeks). Up to 32 cycles of pembrolizumab and 24 months of Pelareorep (2 years) can be administered in the absence of progression, intolerable toxicity, and other discontinuation criteria (See protocol section 4.6).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed to meet screening requirements.</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>On Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Registered on Study</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received First Dose of Study Drugs</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed to meet treatment requirements</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Survival Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only patients who were treated on study were included. 2 patients were screen fails, and 2 patients became ineligible for treatment and did not receive study drug--these patients were not included here.</population>
      <group_list>
        <group group_id="B1">
          <title>Pembrolizumab 200 mg IV + Pelareorep 4.5x10^10 TCID_50</title>
          <description>Pembrolizumab will be administered on Day 1 of each cycle at 200 mg IV over 30 minutes.&#xD;
In Cycle 1, Pelareorep will be administered at a dose of 4.5x10 ^10 TCID_50 over 60 minutes on Days 1, 2, 3 and 8. From Cycle 2 onwards, Pelareorep will be administered at a dose of 4.5x10^10 TCID_50 on Days 1 and 8.&#xD;
Pelareorep will be administered after completion of Pembrolizumab infusion on Day 1 of each cycle.&#xD;
Each cycle is 21 days (3 weeks). Up to 32 cycles of pembrolizumab and 24 months of Pelareorep (2 years) can be administered in the absence of progression, intolerable toxicity, and other discontinuation criteria (See protocol section 4.6).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1</title>
        <description>To determine the overall response rate (ORR) by RECIST v 1.1 criteria for the combination of pembrolizumab with pelareorep. ORR is defined as the number of patients who have a complete or partial response to therapy (CR or PR). The Simon 2 stage design for this study requires 2 or more PR or CR in Stage 1 to continue accrual for Stage 2. Per RECIST v. 1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.&#xD;
Patients who have taken one dose of either study drug, and completed the first on study scan (last week of Cycle 3) are evaluable. If a patient drops out of the study before the first scan, due to clinical progression, they are evaluable and will not be replaced.</description>
        <time_frame>Last week of Cycle 3 (1 Cycle = 21 days)</time_frame>
        <population>Although 13 patients received treatment, 1 patient refused treatment after Cycle 1. Their response data was not available for evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab 200 mg IV + Pelareorep 4.5x10^10 TCID_50</title>
            <description>Pembrolizumab will be administered on Day 1 of each cycle at 200 mg IV over 30 minutes.&#xD;
In Cycle 1, Pelareorep will be administered at a dose of 4.5x10 ^10 TCID_50 over 60 minutes on Days 1, 2, 3 and 8. From Cycle 2 onwards, Pelareorep will be administered at a dose of 4.5x10^10 TCID_50 on Days 1 and 8.&#xD;
Pelareorep will be administered after completion of Pembrolizumab infusion on Day 1 of each cycle.&#xD;
Each cycle is 21 days (3 weeks). Up to 32 cycles of pembrolizumab and 24 months of Pelareorep (2 years) can be administered in the absence of progression, intolerable toxicity, and other discontinuation criteria (See protocol section 4.6).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1</title>
          <description>To determine the overall response rate (ORR) by RECIST v 1.1 criteria for the combination of pembrolizumab with pelareorep. ORR is defined as the number of patients who have a complete or partial response to therapy (CR or PR). The Simon 2 stage design for this study requires 2 or more PR or CR in Stage 1 to continue accrual for Stage 2. Per RECIST v. 1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.&#xD;
Patients who have taken one dose of either study drug, and completed the first on study scan (last week of Cycle 3) are evaluable. If a patient drops out of the study before the first scan, due to clinical progression, they are evaluable and will not be replaced.</description>
          <population>Although 13 patients received treatment, 1 patient refused treatment after Cycle 1. Their response data was not available for evaluation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) by RECIST v 1.1</title>
        <description>Kaplan-Meier curves will be used.</description>
        <time_frame>Up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1-year Survival by RECIST v 1.1</title>
        <description>Kaplan-Meier curves will be used.</description>
        <time_frame>At 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Survival by RECIST v 1.1</title>
        <description>Kaplan-Meier curves will be used.</description>
        <time_frame>At 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS) by RECIST v 1.1</title>
        <description>Kaplan-Meier curves will be used.</description>
        <time_frame>Up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03</title>
        <time_frame>Up to 30 days after last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response Determined by Analysis of pre-and Post- Treatment Biopsies and Blood-based Immune Markers</title>
        <description>Will be assessed for change using paired statistical methods such as paired t-tests or signed rank tests.</description>
        <time_frame>Up to 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected over a 2 year period. Each patient was followed from the time of treatment, during treatment at the beginning of each cycle through 30 days post last treatment, where 1 Cycle = 21 days the range of cycles attempted was 1-9.</time_frame>
      <desc>SAEs are collected from time of consent, and through 30 days post last dose of treatment (thus may include screen-fail patients who did not initiate treatment). All-Cause Mortality and Other Adverse Events are not monitored/assessed for screen-fail patients. Data collection for all-cause mortality and other adverse events begins at the time of treatment initiation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pembrolizumab 200 mg IV + Pelareorep 4.5x10^10 TCID_50</title>
          <description>Pembrolizumab will be administered on Day 1 of each cycle at 200 mg IV over 30 minutes.&#xD;
In Cycle 1, Pelareorep will be administered at a dose of 4.5x10 ^10 TCID_50 over 60 minutes on Days 1, 2, 3 and 8. From Cycle 2 onwards, Pelareorep will be administered at a dose of 4.5x10^10 TCID_50 on Days 1 and 8.&#xD;
Pelareorep will be administered after completion of Pembrolizumab infusion on Day 1 of each cycle.&#xD;
Each cycle is 21 days (3 weeks). Up to 32 cycles of pembrolizumab and 24 months of Pelareorep (2 years) can be administered in the absence of progression, intolerable toxicity, and other discontinuation criteria (See protocol section 4.6).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>One patient did not receive any study drug--they were included as SAEs are monitored at time of consent. This patient also experienced dehydration at the time of the SAE.&#xD;
One patient also experienced back pain at the time of this SAE.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Obstruction Gastric</sub_title>
                <description>One patient also experienced anemia, lymphocyte count decrease, hypoalbuminemia, and nausea at the time of this SAE. One patient also experienced nausea, vomiting, abdominal pain, and duodenal ulcer at the time of this SAE.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>This patient also experienced fatigue, hyponatremia, nausea, and vomiting at the time of this SAE.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis infective</sub_title>
                <description>This patient also experienced stroke at the time of this SAE.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access Complication (RUE DVT)</sub_title>
                <description>This patient also experienced anemia, bloody stool, and duodenal hemorrhage at the time of this SAE.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lymphocyte decreased</sub_title>
                <description>This patient also epxerienced nausea, anemia, and hypoalbuminemia at the time of this SAE.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <description>This patient also experienced stroke at the time of this SAE.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <description>One patient also experienced Death NOS at the time of this SAE.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <description>This patient also experienced depressed level of consciousness, and hypoxia at the time of this SAE. This patient did not receive any study drug. They were included because SAEs are monitored at the time of consent.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Duodenal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim analysis criteria to move onto Stage 2 of the Simon 2 stage design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Devalingam Mahalingam MD, PhD Associate Professor, Division of Hematology and Oncology</name_or_title>
      <organization>Northwestern University, Feinberg School of Medicine</organization>
      <phone>312-695-6929</phone>
      <email>mahalingam@nm.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

